RC
JANX icon

Rangeley Capital’s Janux Therapeutics JANX Stock Holding History

Rangeley Capital’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Sell
97,978
-24,522
-20% -$355K 1.37% 20
2026
Q1 		$1.7M Buy
122,500
+97,086
+382% +$1.33M 1.65% 20
2025
Q4 		$351K Buy
+25,414
New +$598K 0.29% 64

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Rangeley Capital's JANX Position: Q2 2026 in Review

Rangeley Capital reduced its Janux Therapeutics (JANX) stake by 20% in Q2 2026, selling an estimated $355K and leaving 97,978 shares worth $1.5M. The position accounts for 1.37% of the portfolio, ranked #20.

Rangeley Capital first reported a position in JANX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.7M in Q1 2026. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Rangeley Capital held 97,978 shares of Janux Therapeutics worth $1.5M as of Q2 2026.
  • Rangeley Capital sold 24,522 Janux Therapeutics shares in Q2 2026, an estimated $355K.
  • Janux Therapeutics made up 1.37% of Rangeley Capital's portfolio in Q2 2026, its #20 holding.
  • Rangeley Capital first reported a position in Janux Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rangeley Capital's Janux Therapeutics position peaked at $1.7M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.